Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs – 2

Forbes July 16, 2024
Robert Hart

Topline

The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market — here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.

Key Facts

What New Drugs Are Eli Lilly And Novo Nordisk Working On After Ozempic And Mounjaro?

While semaglutide and tirzepatide—respectively the generic names for the active drug in Wegovy, Ozempic, Mounjaro, and Zepbound—dominate the weight loss drug market (Mounjaro and Ozempic are only licensed for diabetes), neither Novo Nordisk nor Eli Lilly are resting on their laurels. Both are refining existing medications and developing next generation drugs to shore up their position...

Today's Sponsors

Today's Sponsor